Peptide-based PET quantifies target engagement of PD-L1 therapeutics
JournalJournal of Clinical Investigation
PublisherAmerican Society for Clinical Investigation
MetadataShow full item record
AbstractImmune checkpoint therapies have shown tremendous promise in cancer therapy. However, tools to assess their target engagement, and hence the ability to predict their efficacy, have been lacking. Here, we show that target engagement and tumor-residence kinetics of antibody therapeutics targeting programmed death ligand-1 (PD-L1) can be quantified noninvasively. In computational docking studies, we observed that PD-L1-targeted monoclonal antibodies (atezolizumab, avelumab, and durvalumab) and a high-affinity PD-L1-binding peptide, WL12, have common interaction sites on PD-L1. Using the peptide radiotracer [64Cu]WL12 in vivo, we employed positron emission tomography (PET) imaging and biodistribution studies in multiple xenograft models and demonstrated that variable PD-L1 expression and its saturation by atezolizumab, avelumab, and durvalumab can be quantified independently of biophysical properties and pharmacokinetics of antibodies. Next, we used [64Cu]WL12 to evaluate the impact of time and dose on the unoccupied fraction of tumor PD-L1 during treatment. These quantitative measures enabled, by mathematical modeling, prediction of antibody doses needed to achieve therapeutically effective occupancy (defined as >90%). Thus, we show that peptide-based PET is a promising tool for optimizing dose and therapeutic regimens employing PD-L1 checkpoint antibodies, and can be used for improving therapeutic efficacy. Copyright 2018 American Society for Clinical Investigation. All right reserved.
SponsorsWe would like thank the University of Wisconsin and Washington University Cyclotron teams for 64CuCl2 production. Funding for this study was provided by Allegheny Health Network-Johns Hopkins Cancer Research Fund (to SN), NIH 1R01CA236616 (to SN), and NIH P41EB024495 (to MGP). Core resources (flow cytometry, histology, and imaging) were supported by NIH P30CA006973.
Keywordprogrammed death ligand-1
immune checkpoint therapeutics
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85060855025&doi=10.1172%2fJCI122216&partnerID=40&md5=0e01ca87ec600363f7e1e39386eb90d0; http://hdl.handle.net/10713/8708
- Peptide-Based <sup>68</sup>Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer.
- Authors: De Silva RA, Kumar D, Lisok A, Chatterjee S, Wharram B, Venkateswara Rao K, Mease R, Dannals RF, Pomper MG, Nimmagadda S
- Issue date: 2018 Sep 4
- Rapid PD-L1 detection in tumors with PET using a highly specific peptide.
- Authors: Chatterjee S, Lesniak WG, Miller MS, Lisok A, Sikorska E, Wharram B, Kumar D, Gabrielson M, Pomper MG, Gabelli SB, Nimmagadda S
- Issue date: 2017 Jan 29
- Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
- Authors: Mayer AT, Natarajan A, Gordon SR, Maute RL, McCracken MN, Ring AM, Weissman IL, Gambhir SS
- Issue date: 2017 Apr
- Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.
- Authors: Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS
- Issue date: 2017 Jul 17
- PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
- Authors: Lesniak WG, Chatterjee S, Gabrielson M, Lisok A, Wharram B, Pomper MG, Nimmagadda S
- Issue date: 2016 Sep 21